Targeting STAT3 in Ovarian Cancer- Center for Integrated Biomedical and Bioengineering (CIBBR)

Information

  • Research Project
  • 10395120
  • ApplicationId
    10395120
  • Core Project Number
    P20GM113131
  • Full Project Number
    3P20GM113131-05S2
  • Serial Number
    113131
  • FOA Number
    PA-20-272
  • Sub Project Id
  • Project Start Date
    8/1/2017 - 6 years ago
  • Project End Date
    5/31/2022 - 2 years ago
  • Program Officer Name
    BERNAL, FEDERICO
  • Budget Start Date
    6/1/2021 - 3 years ago
  • Budget End Date
    5/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    05
  • Suffix
    S2
  • Award Notice Date
    9/9/2021 - 2 years ago

Targeting STAT3 in Ovarian Cancer- Center for Integrated Biomedical and Bioengineering (CIBBR)

PROJECT SUMMARY Ovarian cancer remains a deadly disease in part due to ovarian cancer metastasis. Spheroids, clusters of ovarian cancer cells, interact and clear the protective mesothelial layer that lines the peritoneum in the early stages of ovarian cancer metastasis. There is a gap in knowledge regarding the signaling pathways and genes involved in mesothelial clearance. By not knowing these pathways, this may affect the ability to design drugs to target ovarian cancer metastasis. The STAT3 signaling pathway plays a role in mesothelial clearance. However, it is not known how the interaction of ovarian spheroids with mesothelial cells affects STAT3 activation in ovarian cancer cells. Endometriosis, a benign disease that may promote infertility and increase risk for ovarian cancer, has some similarities to ovarian cancer as the endometrioid cells also interact with the mesothelial cells, and STAT3 activation is elevated in patients with endometriosis. Statins, inhibitors of HMGCR, are often used to lower cholesterol; however, there is evidence that statins also inhibit STAT3. The long-term objective of this work is to develop drugs for the treatment of metastatic ovarian cancer. The central hypothesis is that interaction with mesothelial cells modulates STAT3 activity that can be attenuated with statin treatment. Aim 1 will determine the effects of interacting with mesothelial cells on STAT3 activation and define the mechanism of STAT3 inhibition by statins. Aim 2 will determine STAT3 target gene expression changes during mesothelial clearance that are blocked by statin treatment using single cell RNA-seq. Ovarian cancer cells will be compared to endometrioid cells to potentially identify cancer specific STAT3 target genes. Overall, the outcomes of the proposed work may provide a more complete understanding of the role of STAT3 in ovarian cancer metastasis and provide insight into the role of STAT3 in endometriosis, two gynecologic diseases that may greatly impact women across their lifespan.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    P20
  • Administering IC
    GM
  • Application Type
    3
  • Direct Cost Amount
    200000
  • Indirect Cost Amount
    100688
  • Total Cost
    300688
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
    EARTH SCIENCES/RESOURCES
  • Funding ICs
    NCI:300688\
  • Funding Mechanism
    RESEARCH CENTERS
  • Study Section
    ZGM1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIVERSITY OF NEW HAMPSHIRE
  • Organization Department
    BIOCHEMISTRY
  • Organization DUNS
    111089470
  • Organization City
    DURHAM
  • Organization State
    NH
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    038242620
  • Organization District
    UNITED STATES